The sale is a routine post-vesting disposition by an officer with no unusual size or timing. Monitor for any additional insider selling patterns in future filings.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $32.00entry
- T+1 · 13d ago +6.41%α +4.75% · $34.05
- T+5 · 7d ago −14.42%α −13.83% · $27.39
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Todd Watanabe, an officer of Arcutis Biotherapeutics, filed a Form 144 on November 2, 2026, indicating intent to sell 4,377 shares of common stock with an approximate market value of $139,466. The shares were acquired via restricted stock vesting on November 1, 2026. This is a routine sale following vesting, representing a small fraction of the company's $4.0B market cap.
Key Facts
- Insider Todd Watanabe (officer) filed Form 144 to sell 4,377 shares of common stock.
- Estimated value of proposed sale: $139,466.
- Shares acquired via restricted stock vesting on November 1, 2026.
- Proposed sale date: November 2, 2026.
- Company market cap: $4.0B; sale represents ~0.0035% of market cap.
- Recent insider activity (30 days): 1 sell totaling $127K.
Financial Impact
Proposed sale of 4,377 shares valued at $139,466, or ~0.0035% of market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur.
- No unusual signals from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-068988 |
| Document: 0001628280-26-068988-index.html | 0001628280-26-068988 |
| Document: 0001628280-26-068988.txt | 0001628280-26-068988 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers